期刊文献+

免疫磁珠分选与顺铂富集喉癌Hep-2细胞系中肿瘤干细胞的比较 被引量:2

Comparation of magnetic activated cell sorting and chemotherapy agent DDP in enriching cancer stem cell of laryngeal carcinoma cell line Hep-2
原文传递
导出
摘要 目的比较免疫磁珠分选(MACS)及化疗药物顺铂(DDP)筛选富集喉癌Hep-2细胞系肿瘤干细胞的效果。方法以CD133MACS、DDP作用两种方法来富集喉癌Hep-2细胞系中的肿瘤干细胞,并以流式细胞术(FCM)检测处理后CD133^+细胞的百分率。同时观察细胞形态学的改变,判断两种方法分选后细胞对后续实验的影响。结果经FCM检测,MACS分选喉癌Hep-2,CD133^+细胞得率为64.33%,不同浓度DDP作用于喉癌Hep-2细胞48h,FCM检测CD133^+细胞有不同的得率,其中质量浓度为4μg/ml时,所得CD133^+≥细胞百分率最高,为50.7%。MACS与DDP各组比较差异均有统计学意义(P〈0.01);两种方法处理后MACS组细胞的存活状态要好于DDP组。结论MACS分选纯度较高,对细胞损伤小,适合后续培养;但分选前耗时长,每次分选仅能用于一种Marker。DDP筛选简单易行,符合临床肿瘤干细胞(CSC)抵抗化疗的模式。但阳性细胞得率与细胞毒性成正比。MACS和DDP筛选肿瘤干细胞各有其优势及适用范围,实验中可根据不同目的来确定所用筛选方法。 Objective To compare effect of chemotherapy agent DDP to MACS in sorting cancer stem cells (CSC) of laryngeal carcinoma cell line Hep-2. Methods CD133 magnetic beads were applied to sort Hep-2 cells. Different dosages of DDP were used to treat Hep-2 cells for 48 hours. Enrichment rate of CD133^+ cells by MACS and after DDP treatment was detected by Flow Cytometer (FCM). Morphologic change was observed under inverse-phase microscope. Results FCM showed that the sorting rate of CD133^+ cells through MACS was 64.33 %, while after DDP treatment for 48 hours, the rate of CD133^+ cells was enriched significantly in each dosage of DDP, with the maximal rate was 50.7 %, in the dosage of 4 μg/ml. There was a significantly difference between MACS and each of DDP group (P 〈0.01). Cells treated with DDP were abnormal in morphology. Conclusion MACS and DDP sorting has respective advantages in enriching CSC in Hep-2 cell lines.
出处 《肿瘤研究与临床》 CAS 2009年第5期304-307,共4页 Cancer Research and Clinic
关键词 肿瘤干细胞 富集 免疫磁珠分选 化疗药物 CD133 Cancer stem cell (CSC) Enrich Magnetic activated cell sorting (MACS) Chemotherapy agents: CD133
  • 相关文献

参考文献7

  • 1Bonnet D,Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietie cell.Nat Med,1997,3:730-737.
  • 2Singh SK,Hawkins C,Clarke ID,et al.Identification of human brain tumour initiating cells.Nature,2004,432:396-401.
  • 3Zhou L,Wet X,Cheng L,et al.CD133,one of the markers of cancer stem cells in Hep-2 cell line.Laryngnscope,2007,117:455-460.
  • 4Nishi H,Nishmura S,Higashiura M,et al.A new method for histamine release from peripheral blood basophile using monoclonal antibody-coated magnetic beads.J lmmunol methods,2000,240:39-46.
  • 5Beier D,Hau P,Proeseholdt M,et el.CD133+ and CD133-glioblestoma-derived cancer stem cells show differential growth characteristics and molecular profiles.Cancer Res,2007,67:4010-4015.
  • 6余爽,张京钟,张海燕,赵春礼,徐群渊.免疫磁珠体外纯化人胎脑中CD133阳性干细胞的实验研究[J].神经解剖学杂志,2004,20(3):271-274. 被引量:6
  • 7Bao S,Wu Q,McLendon BE,et al.Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.Nature,2006,444:756-760.

二级参考文献11

  • 1[1]Gage FH. Mammalian neural stem cells. Science, 2000; 287(5475): 1443- 1448
  • 2[2]Uchida N, Buck DW, He D et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA,2000; 97:14720- 14725
  • 3[3]Suslov ON, Kukekov VG, Ignatova TN et al. Neural stem cell heterogeneity demonstrated by molecular phenotyping of clonal neurospheres. Proc Natl Acad Sci USA, 2002; 29 : 14506-14511
  • 4[4]Kemshead JT, Ugelstad J. Magnetic separation techniques:their application to medicine. Mol Cell Biochem, 1985; 67:11-18
  • 5[5]Miltenyi S, Muller W, Weichel W et al. High gradient magnetic cells separation with MACS. Cytometry, 1990;11: 231-238
  • 6[6]Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood,1997;90:5002-5012
  • 7[7]Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 2000;95:952-958
  • 8[8]Miraglia S, Godfrey W, Yin AH. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization,and molecular cloning. Blood, 1997;90:5013-5021
  • 9[9]Tamaki S, Eckert K, He D et al. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J NeurosciRes, 2002;69:976-986
  • 10[10]Weigmann A, Corbeil D, Hellwig A et al. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA, 1997;94:12425-12430

共引文献5

同被引文献18

  • 1Clement V Sanchez P de Tribolet N Radovanovic I Ruiz i Altaba A.HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity[J].中国神经肿瘤杂志,2007,5(2):122-122. 被引量:97
  • 2Yin AH,Miraglia S,Zanjani ED,et al.AC133,a novel marker for human hematopoietic stem and progenitor cells.Blood,1997,90:5002-5012.
  • 3Singh SK,Hawkins C,Clarke ID,et al.Identification of human brain tumour initiating cells.Nature,2004,432:396-401.
  • 4Collins AT,Berry PA,Hyde C,et al.Prospective identification of tumorigenic prostate cancer stem cells.Cancer Res,2005,65:10946-10951.
  • 5Ferrandina G,Petrillo M,Bonanno G,et al.Targeting CD133 antigen in cancer.Expert Opin Ther Targets,2009,13:823-837.
  • 6Deckert PM.Current constructs and targets in clinical development for antibody-based cancer therapy.Curr Drug Targets,2009,10:158-175.
  • 7Krebber A,Bormhauser S,Burmester J,et al.Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system.J Immunol Methods,1997,201:35-55.
  • 8Borrebaeck CAK.Antibody engineering,2nd ed.New York:Oxford University Press,1995:379-387.
  • 9Shmelkov SV,St Clair R,Lyden D,et al.Molecules in focus AC133/CD133/Prominin-1.Int J Biochem Cell Biol,2005,37:715-719.
  • 10Ieta K,Tanaka F,Haraguehi N,et al.Biological and genetic characteristics of tumor-initiating cells in colon cancer.Ann Surg Oncol,2008,15:638-648.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部